Zhou Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhou Han has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Gene Liau
Stoke Therapeutics Inc., Bedford, MA 01730, USA
2 shared publicationsSophina Ji
Stoke Therapeutics Inc., Bedford, MA 01730, USA
2 shared publicationsAditya Venkatesh
Stoke Therapeutics, Inc., Bedford, MA, USA
1 shared publicationAnna Corrionero
Stoke Therapeutics, Inc., Bedford, MA, USA
1 shared publicationAnne Christiansen
Stoke Therapeutics Inc., Bedford, MA 01730, USA
1 shared publicationBarry Ticho
Stoke Therapeutics, Inc., Bedford, MA, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 26 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (558)
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
Antisense oligonucleotide administration reduces seizures and SUDEP incidence in a mouse model of Dravet syndrome.
- 26 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (558)
Top Cited PapersAntisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
Antisense oligonucleotide administration reduces seizures and SUDEP incidence in a mouse model of Dravet syndrome.
- Open Access
- 9 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-13
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
While most monogenic diseases are caused by loss or reduction of protein function, the need for technologies that can selectively increase levels of protein in native tissues remains. Here we demonstrate that antisense-mediated modulation of pre-mRNA splicing can increase endogenous expression of full-length protein by preventing naturally occurring non-productive alternative splicing and promoting generation of productive mRNA. Bioinformatics analysis of RNA sequencing data identifies non-productive splicing events in 7,757 protein-coding human genes, of which 1,246 are disease-associated. Antisense oligonucleotides targeting multiple types of non-productive splicing events lead to increases in productive mRNA and protein in a dose-dependent manner in vitro. Moreover, intracerebroventricular injection of two antisense oligonucleotides in wild-type mice leads to a dose-dependent increase in productive mRNA and protein in the brain. The targeting of natural non-productive alternative splicing to upregulate expression from wild-type or hypomorphic alleles provides a unique approach to treating genetic diseases.
- 9 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-13
Open AccessAntisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
While most monogenic diseases are caused by loss or reduction of protein function, the need for technologies that can selectively increase levels of protein in native tissues remains. Here we demonstrate that antisense-mediated modulation of pre-mRNA splicing can increase endogenous expression of full-length protein by preventing naturally occurring non-productive alternative splicing and promoting generation of productive mRNA. Bioinformatics analysis of RNA sequencing data identifies non-productive splicing events in 7,757 protein-coding human genes, of which 1,246 are disease-associated. Antisense oligonucleotides targeting multiple types of non-productive splicing events lead to increases in productive mRNA and protein in a dose-dependent manner in vitro. Moreover, intracerebroventricular injection of two antisense oligonucleotides in wild-type mice leads to a dose-dependent increase in productive mRNA and protein in the brain. The targeting of natural non-productive alternative splicing to upregulate expression from wild-type or hypomorphic alleles provides a unique approach to treating genetic diseases.